Personalised prevention in action across European health systems: lessons from the PROPHET Framework
Abstract
Background: Personalised prevention (PP) aims to target interventions based on the combination of biological, lifestyle and socioeconomic factors, but requires structured approaches integrating organisational, equity, societal dimensions. The EU-funded project PeRsOnalized Prevention roadmap for the future HEalThcare (PROPHET) had recently proposed an implementation framework for PP interventions, combining Health Technology Assessment (HTA), Health Impact Assessment (HIA), and monitoring aspects. This study investigates its potential uptake across European health systems.
Methods: We conducted semi-structured interviews with high-level stakeholders in four countries (Italy, the Netherlands, Finland, and Estonia), representing different health system models. Participants included representatives from ministries, academia, clinical practice, patient networks. Interviews explored system readiness for the PROPHET Framework applicability focusing on governance, evaluation, and monitoring.
Results: Twenty-four stakeholders were interviewed (Italy n = 7; the Netherlands n = 5; Finland n = 7; Estonia n = 5). PP remains at an early stage, with limited system readiness. Contextual differences emerged: Finland shows strong data but limited implementation; the Netherlands strong HTA but weaker integration of HIA and monitoring; Italy regional heterogeneity; Estonia mixed readiness with workforce gaps. Common barriers emerged: governance as the main challenge, with unclear roles and weak coordination. Limited HIA institutionalisation, fragmented monitoring, data gaps constrain implementation. The PROPHET Framework was seen as valuable, but its uptake is limited by structural constraints.
Conclusions: Similar barriers affect uptake across countries. Strengthening governance, clarifying roles, and integrating HTA, HIA and monitoring into decision-making are key priorities. The PROPHET Framework is promising but needs alignment with national contexts and stronger coordination.
Key messages: • Personalised prevention in Europe remains at an early stage, with limited system readiness and persistent governance challenges across countries.
• The PROPHET Framework offers a valuable approach to advancing personalised prevention, though its uptake is still limited by systemic barriers.
Related
- Scaling prevention systems through workforce training: the European prevention curriculum
- SRIA for personalised prevention and EU roadmap for implementation
- Personalised cardiovascular prevention in primary care: feasibility results from the FitPreV trial
- Conducting ethical drug research in prisons: lessons learnt from the implementation of the European Questionnaire on Drug use among People living in Prison (EQDP)
- Phenological responses to temperature are similar across spatial and temporal gradients - lessons learned from European long-term data.
BibTeX
@article{giacobini2026personalised,
title = {{Personalised prevention in action across European health systems: lessons from the PROPHET Framework}},
author = {E Giacobini and S Farina and A Sabatelli and A Valz Gris and P Kannan and C Van El and A Reigo and A Metspalu and R Pastorino and S Boccia},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.390},
url = {https://doi.org/10.1093/eurpub/ckag169.390},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Personalised prevention in action across European health systems: lessons from the PROPHET Framework
AU - E Giacobini
AU - S Farina
AU - A Sabatelli
AU - A Valz Gris
AU - P Kannan
AU - C Van El
AU - A Reigo
AU - A Metspalu
AU - R Pastorino
AU - S Boccia
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.390
UR - https://doi.org/10.1093/eurpub/ckag169.390
AB - Background: Personalised prevention (PP) aims to target interventions based on the combination of biological, lifestyle and socioeconomic factors, but requires structured approaches integrating organisational, equity, societal dimensions. The EU-funded project PeRsOnalized Prevention roadmap for the future HEalThcare (PROPHET) had recently proposed an implementation framework for PP interventions, combining Health Technology Assessment (HTA), Health Impact Assessment (HIA), and monitoring aspects. This study investigates its potential uptake across European health systems. Methods: We conducted semi-structured interviews with high-level stakeholders in four countries (Italy, the Netherlands, Finland, and Estonia), representing different health system models. Participants included representatives from ministries, academia, clinical practice, patient networks. Interviews explored system readiness for the PROPHET Framework applicability focusing on governance, evaluation, and monitoring. Results: Twenty-four stakeholders were interviewed (Italy n = 7; the Netherlands n = 5; Finland n = 7; Estonia n = 5). PP remains at an early stage, with limited system readiness. Contextual differences emerged: Finland shows strong data but limited implementation; the Netherlands strong HTA but weaker integration of HIA and monitoring; Italy regional heterogeneity; Estonia mixed readiness with workforce gaps. Common barriers emerged: governance as the main challenge, with unclear roles and weak coordination. Limited HIA institutionalisation, fragmented monitoring, data gaps constrain implementation. The PROPHET Framework was seen as valuable, but its uptake is limited by structural constraints. Conclusions: Similar barriers affect uptake across countries. Strengthening governance, clarifying roles, and integrating HTA, HIA and monitoring into decision-making are key priorities. The PROPHET Framework is promising but needs alignment with national contexts and stronger coordination. Key messages: • Personalised prevention in Europe remains at an early stage, with limited system readiness and persistent governance challenges across countries. • The PROPHET Framework offers a valuable approach to advancing personalised prevention, though its uptake is still limited by systemic barriers.
SN - 1101-1262
SN - 1464-360X
ER -